Patents by Inventor MATTEO GENTILI

MATTEO GENTILI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10969389
    Abstract: The present invention provides an in vitro method for monitoring interphase nuclear envelope rupture events in a eukaryotic cell or screening or identifying compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in a eukaryotic cell. These methods relate on a protein having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity. Interphase nuclear envelope rupture events are characterized by the presence of the protein of the invention in the nucleus of the eukaryotic cell.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 6, 2021
    Assignees: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Matthieu Piel, Matteo Gentili, Matthew Raab, Nicolas Manel
  • Publication number: 20190105381
    Abstract: The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides and its use for treating cancer.
    Type: Application
    Filed: March 16, 2016
    Publication date: April 11, 2019
    Inventors: NICOLAS MANEL, MATTEO GENTILI, SATOH TAKESHI, JAN REHWINKEL, ANNE BRIDGEMAN, TAMARA DAVENNE, JONATHAN MAELFAIT
  • Publication number: 20190033311
    Abstract: The present invention provides an in vitro method for monitoring interphase nuclear envelope rupture events in a eukaryotic cell or screening or identifying compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in a eukaryotic cell. These methods relate on a protein having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity. Interphase nuclear envelope rupture events are characterized by the presence of the protein of the invention in the nucleus of the eukaryotic cell.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 31, 2019
    Inventors: MATTHIEU PIEL, MATTEO GENTILI, MATTHEW RAAB, NICOLAS MANEL
  • Publication number: 20180296667
    Abstract: The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 18, 2018
    Inventors: NICOLAS MANEL, MATTEO GENTILI, SATOH TAKESHI, JAN REHWINKEL, ANNE BRIDGEMAN, TAMARA DAVENNE, JONATHAN MAELFAIT
  • Patent number: 10010607
    Abstract: The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 3, 2018
    Assignees: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Nicolas Manel, Matteo Gentili, Satoh Takeshi, Jan Rehwinkel, Anne Bridgeman, Tamara Davenne, Jonathan Maelfait
  • Publication number: 20160074507
    Abstract: The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.
    Type: Application
    Filed: September 16, 2015
    Publication date: March 17, 2016
    Inventors: NICOLAS MANEL, MATTEO GENTILI, SATOH TAKESHI, JAN REHWINKEL, ANNE BRIDGEMAN, TAMARA DAVENNE, JONATHAN MAELFAIT